Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051035 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of KO-947 in Non-Hematological Malignancies
A Phase 1 study, sponsored by Kura Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT03051035: Clinical Trial Phase 1 study, sponsored by Kura Oncology.
NCT03051035 is a Phase 1 study that was terminated before completion, run by Kura Oncology. The registered enrollment target is 61 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03051035, a Phase 1 study, was terminated before completion, sponsored by Kura Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity.
Interventions
- DRUG KO-947
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 1 |
Why NCT03051035 stopped before completion
NCT03051035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which KO-947 is the first listed.
NCT03051035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03051035 about?
NCT03051035 is a clinical study titled "First-in-Human Study of KO-947 in Non-Hematological Malignancies". This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D...
What is the current status of trial NCT03051035?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2017-04-06. Estimated completion is 2020-06-02.
What interventions are being tested in trial NCT03051035?
The interventions under investigation include: KO-947 (DRUG).
Who is sponsoring clinical trial NCT03051035?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03051035's enrollment target sits among peer trials
61 828th of 2000 higher than 1,170 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI